Author's response to reviews

Title: Efficacy of omalizumab (Xolair) in patients with moderate to severe asthma in Taiwan: a retrospective, population-based database cohort study

Authors:

Hao-Cheng Chen (haochengenator@gmail.com)
Chien-Da Huang (cdhuang@adm.cgmh.org.tw)
Erin Chang (erin.chang@novartis.com)
Han-Pin Kuo (q8828@ms11.hinet.net)

Version: 2 Date: 20 June 2015

Author's response to reviews:

June 20, 2015

Section Editor-in-Chief: Joerg Mattes
University of Newcastle, Australia
BMC Pulmonary Medicine

Dear Professor Mattes:

We respectfully submit our revised manuscript entitled “Efficacy of omalizumab (Xolair#) in patients with moderate to severe asthma in Taiwan: a retrospective, population-based database cohort study”. We have revised our manuscript to include line and page numbers in the main text file to facilitate peer-review.

The submitted revised manuscript is an original article. It has not been published previously or is under consideration for publication in any other journals. We have carefully proofread and edited the manuscript.

Omalizumab (Xolair#), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We used data from the National Health Insurance Research Database to investigate the prescribing patterns of omalizumab and its efficacy, discontinuation and medical resource utilization in Taiwan. This study revealed that patients who received omalizumab therapy for over 4 months were more likely to reduce the use of other asthma medications and less likely to experience an asthma exacerbation, ER visits, and hospitalization. There were also reductions in asthma medications, exacerbations and ER visits after discontinuation of omalizumab at 2, 6 and 12 months compared with baseline. These data suggest that omalizumab has efficacy in improving health outcomes in patients with moderate to severe asthma in a real-life setting.

We truly hope the manuscript will meet the quality of BMC Pulmonary Medicine and we are looking forward to hearing your decision.
Sincerely yours,

Chien-Da Huang M.D.
Associate Professor of Department of Thoracic Medicine
Physician Educator of Department of Medical Education
Chang Gung Memorial Hospital
Chang Gung University College of Medicine
199 Tun-Hwa .N. Rd.
Taipei 105, Taiwan